Vaccines help prevent the spread of disease by leveraging the immune system. Preventative vaccines help develop immunity to a disease by imitating, but not causing, an infection. Therapeutic vaccines help the body identify and target diseased cells.
In the United States, 16 diseases are now preventable as a result of childhood vaccines, resulting in an estimated $1.4 trillion in societal costs saved.
Since peaking in 1991, the death rate associated with cancer declined by 29%, which translates to 2.9 million fewer cancer deaths.
Janssen is one among dozens of biopharmaceutical companies working around the clock to identify and develop safe and effective vaccines to prevent COVID-19.
Over the years, treatments for infectious diseases have grown steadily more complex, and today, our ability to respond to diseases like COVID-19 is radically different than it would have been even a few decades ago.
As people across the globe continue to be impacted by COVID-19, the disease caused by a new strain of coronavirus, biopharmaceutical companies have rapidly taken action to research and develop potential new medicines, while partnering with public health leaders worldwide, to combat this global public health emergency.
At a recent event held by The Atlantic, scientists and researchers joined others in the biopharmaceutical industry to discuss genomics' ever-evolving and critically important role in treating disease.
After centuries without viable cancer treatments, scientists are more hopeful than ever before as they learn more about different types of the disease. We're taking a look at the advancements that have occurred over the last decade.